Advaxis (Advaxis) Days Inventory

: 0.00 (As of Mar. 2023)

View and export this data going back to 2005. Start your Free Trial

Days Inventory is also known as Days Sales of Inventory (DSI). Advaxis's Average Total Inventories for the three months ended in Mar. 2023 was $0.00 Mil. Advaxis's Cost of Goods Sold for the three months ended in Mar. 2023 was $0.00 Mil. Hence, Advaxis's Days Inventory for the three months ended in Mar. 2023 was 0.00.

The historical rank and industry rank for Advaxis's Days Inventory or its related term are showing as below:

ADXS's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 191.36
* Ranked among companies with meaningful Days Inventory only.

Advaxis's Days Inventory stayed the same from Jan. 2022 (0.00) to Mar. 2023 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Advaxis's Inventory-to-Revenue for the three months ended in Mar. 2023 was 0.00.

Advaxis Days Inventory Historical Data

The historical data trend for Advaxis's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advaxis Annual Data

Trend

Oct13

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Days Inventory

Get a 7-Day Free Trial

Advaxis Quarterly Data
	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Mar23
Days Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Advaxis's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advaxis Days Inventory Distribution

For the Biotechnology industry and Healthcare sector, Advaxis's Days Inventory distribution charts can be found below:

* The bar in red indicates where Advaxis's Days Inventory falls into.

Advaxis Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Advaxis's Days Inventory for the fiscal year that ended in Oct. 2022 is calculated as

	Days Inventory (A: Oct. 2022 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Oct. 2021 )	+	Total Inventories (A: Oct. 2022 ))	/	count )	/	Cost of Goods Sold (A: Oct. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Advaxis's Days Inventory for the quarter that ended in Mar. 2023 is calculated as:

	Days Inventory (Q: Mar. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Oct. 2022 )	+	Total Inventories (Q: Mar. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0.004	*	365 / 4
=	0					/	0.004	*	365 / 4
=	0.00

Advaxis (OTCPK:ADXS) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Advaxis's Inventory Turnover for the three months ended in Mar. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0.004	/	0
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Advaxis's Inventory to Revenue for the three months ended in Mar. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0.004
	=	0.00

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Advaxis Days Inventory Related Terms

Thank you for viewing the detailed overview of Advaxis's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Advaxis (Advaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advaxis Inc (OTCPK:ADXS) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 8540

Website

https://www.advaxis.com

Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.

Executives

Roy Golan	officer: Chief Financial Officer	24 GOLDA MEIR ST., HOLON L3 5840425
Yuval Cabilly	director	C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348
Pini Orbach	director	C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802
Bridget A Martell	director	C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Israel Biotech Fund Ii, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Israel Biotech Fund Gp Partners Ii, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Murray A Goldberg	director	2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Vered Bisker-leib	director	C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Amoon Growth Fund Limited Partnership	10 percent owner	34 YERUSHALAYIM RD., RAANANA L3 4350110
Israel Biotech Fund Gp Partners, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Yair Chaim Schindel	10 percent owner	YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
I.b.f. Management Ltd.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Igor Gitelman	officer: Chief Accounting Officer	201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070